Scarica l'app Stockscreener
13.80
0.22%
-0.03
Dopo l'orario di chiusura:
13.91
0.11
+0.80%
Precedente Chiudi:
$13.83
Aprire:
$13.83
Volume 24 ore:
1.41M
Relative Volume:
0.79
Capitalizzazione di mercato:
$830.04M
Reddito:
$439.00K
Utile/perdita netta:
$-105.64M
Rapporto P/E:
-7.6667
EPS:
-1.8
Flusso di cassa netto:
$-60.70M
1 W Prestazione:
-3.56%
1M Prestazione:
-59.52%
6M Prestazione:
-40.26%
1 anno Prestazione:
-74.22%
Intervallo 1D:
$13.62
$13.92
Intervallo di 1 settimana:
$13.62
$14.28
Portata 52W:
$13.62
$61.59
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Confronta JANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
13.80 | 831.84M | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Iniziato | Stifel | Buy |
| 2025-09-10 | Iniziato | Truist | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-11 | Iniziato | Raymond James | Outperform |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week LowHere's What Happened - MarketBeat
Is Janux Therapeutics Inc a good long term investmentEarnings Call Summaries & Exceptional Return Capital - earlytimes.in
Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) - Finviz
TD Cowen Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
What analysts say about Janux Therapeutics Inc stockHead and Shoulders Patterns & High Yield Trading Signals - earlytimes.in
Janux Therapeutics Pipeline Remains on Track as JANX008 Advances, Wedbush Says - marketscreener.com
Janux Completes Phase 1a Dose-escalation In Phase 1 JANX008 Study; Expansion Cohorts To Commence - Nasdaq
Janux completes phase 1a dose-escalation for EGFR cancer drug By Investing.com - Investing.com UK
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - New Castle News
Here are the most and least likely M&A targets in biotech, according to Truist - Seeking Alpha
Janux Therapeutics Earnings Notes - Trefis
How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily
Why Janux Therapeutics Inc. stock is favored by top institutions2025 Buyback Activity & Free Reliable Trade Execution Plans - Улправда
Day Trade: Will Janux Therapeutics Inc. stock benefit from infrastructure spendingAnalyst Upgrade & AI Powered Market Entry Strategies - Улправда
Why Janux Therapeutics Inc. stock remains resilientQuarterly Risk Review & Step-by-Step Trade Execution Guides - Улправда
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Market Rankings: Is Janux Therapeutics Inc. stock supported by strong fundamentalsDay Trade & Verified High Yield Trade Plans - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Big Money Moves: Is Janux Therapeutics Inc. stock supported by strong fundamentalsWeekly Profit Summary & Technical Buy Zone Confirmations - Улправда
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Why Janux Therapeutics Inc. stock remains a top recommendationMarket Rally & AI Driven Stock Movement Reports - Улправда
Is Janux Therapeutics Inc. stock a contrarian buyMarket Activity Summary & Daily Chart Pattern Signals - Улправда
Buyout Rumor: Why Janux Therapeutics Inc. stock is favored by top institutionsWeekly Profit Report & Capital Efficient Trade Techniques - Улправда
Barclays Maintains Janux Therapeutics (JANX) Overweight Recommendation - Nasdaq
Janux Therapeutics (NASDAQ:JANX) Hits New 12-Month LowHere's What Happened - MarketBeat
Squarepoint Ops LLC Raises Stock Position in Janux Therapeutics, Inc. $JANX - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Barchart.com
Wyckoff Accumulation Phase Possible in National Standard India LimitedBlue Chip Stock Analysis & Low Cost Capital Growth - earlytimes.in
Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 - AOL.com
Janux Therapeutics (NASDAQ:JANX) Reaches New 52-Week LowWhat's Next? - MarketBeat
Stempoint Capital LP Has $2.08 Million Stock Position in Janux Therapeutics, Inc. $JANX - MarketBeat
Jump Financial LLC Grows Stock Holdings in Janux Therapeutics, Inc. $JANX - MarketBeat
(JANX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Janux Therapeutics (JANX) price target decreased by 10.88% to 69.30 - MSN
Janux Therapeutics, Inc. (JANX) Shareholder/Analyst CallSlideshow (NASDAQ:JANX) 2025-12-09 - Seeking Alpha
Reassessing Janux Therapeutics (JANX) Valuation After Mixed Market Reaction to New JANX007 Phase 1 Data - Sahm
Officer Robinson Files To Sell 50,000 Of Janux Therapeutics Inc [JANX] - TradingView — Track All Markets
Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test? - Yahoo Finance
Optimistic Buy Rating for Janux Therapeutics Despite Challenges and Promising Market Potential - TipRanks
Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop - Yahoo Finance
Andrew Hollman Meyer Sells 3,333 Shares of Janux Therapeutics (NASDAQ:JANX) Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Janux Therapeutics price target lowered to $32 from $80 at Clear Street - MSN
Janux Therapeutics falls -48.4% - MSN
Janux Therapeutics' (JANX) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Insider Sell: Andrew Meyer Sells Shares of Janux Therapeutics In - GuruFocus
Janux Therapeutics CBO Meyer Andrew Hollman Sells Shares - TradingView — Track All Markets
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound - Stocktwits
Janux Therapeutics Sees Unusually Large Options Volume (NASDAQ:JANX) - MarketBeat
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):